Abstract. Recent tetanus cases associated with male circumcision in Eastern and Southern Africa (ESA) prompted an examination of tetanus immunity by age and sex using multiplex serologic data from community surveys in three ESA countries during 2012-2013. Tetanus seroprotection was lower among children 5-14 years versus 1-4 years of age in Kenya (66% versus 90%) and Tanzania (66% versus 89%), but not in Mozambique (91% versus 88%), where children receive two booster doses in school. Among males ≥ 15 years of age, tetanus seroprotection was lower than females in Kenya (45% versus 96%), Tanzania (28% versus 94%), and Mozambique (64% versus 90%). Tetanus immunity from infant vaccination doses wanes over time, and only women of reproductive age routinely receive booster doses. To prevent immunity gaps in older children, adolescents, and adult men, a life-course vaccination strategy is needed to provide the three recommended tetanus booster doses.
INTRODUCTION
Tetanus continues to be a global public health problem, with the highest disease burden remaining in Africa and southeast Asia. 1, 2 Case fatality ratios for tetanus vary from 10% to 70%, depending on the treatment and age of the patient. 2, 3 Accurate estimation of tetanus cases and deaths is challenged by underreporting of neonatal cases (occurring within the first 28 days of life) and lack of routine reporting of nonneonatal cases in many countries. 2 Globally, tetanus vaccination started in 1974 as part of the Expanded Program on Immunization (EPI), which was implemented in all countries by the mid-1980s. 3 The programmatic goals of tetanus control are eliminating maternal and neonatal tetanus (MNT; < 1 case per 1,000 live births in every district) and preventing tetanus in all age groups. 3 In most countries, infants receive tetanus toxoid-containing vaccine (TTCV), for example, diphtheria-tetanus-pertussis (DTP) or DTP-hepatitis B-Haemophilus influenzae type b (pentavalent), through routine immunization (RI) services at 6, 10, and 14 weeks of age. Women of reproductive age (WRA), defined as 15-49 years of age, also receive up to five doses of TTCV, for example, tetanus toxoid (TT) or tetanus-diphtheria (Td), either during antenatal care visits, mass campaigns, or at school, depending on the country. 3 Since 2006, the World Health Organization (WHO) has recommended three booster doses for both sexes in childhood, adolescence, and early adulthood, but these doses are not provided in many countries, especially in sub-Saharan Africa. [3] [4] [5] After infancy, males might receive tetanus booster doses during treatment of injuries or military service.
Among the 20 countries in the WHO subregion of Eastern and Southern Africa (ESA), all provide the primary series of TTCV to infants (6-, 10-, and 14-week schedule; except for Botswana with a 2-, 3-, and 4-month schedule; and Seychelles with a 3-, 4-, and 5-month schedule) and TTCV booster doses to WRA. 4 MNT elimination (MNTE) has been achieved by all ESA countries, except Kenya, South Sudan, and the Somali region of Ethiopia. Tetanus booster doses for both sexes in childhood and adolescence are included in the immunization schedules of nine ESA countries, with four countries providing the three TTCV booster doses needed for lifelong immunity when vaccination begins in infancy (Table 1) . [3] [4] [5] Voluntary medical male circumcision (VMMC) is performed for adolescent and adult males in 14 ESA countries as part of human immunodeficiency virus prevention programs (Table 1) . 10 During 2012-2016, 12 tetanus cases were determined to be causally associated with VMMC among clients 11-47 years of age in five ESA countries. 2, 10, 11 Tetanus immunity gaps likely exist due to waning immunity from infant doses, but recent serologic evidence from the region is too limited to inform immunization strategies among VMMC clients.
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In the three ESA countries of Tanzania, Mozambique, and Kenya, EPI began in 1975, 1979, and 1980 , and WHO-United Nations Children's Fund (UNICEF) estimates of national coverage with the third dose of DTP (DTP3) vaccine among children < 12 months of age in 2013 were 91%, 78%, and 76%, respectively. 12 Of the three countries, only Mozambique provides two childhood TTCV booster doses to both sexes in the first and second grades of school (Table 1) . 4, 5 To evaluate immunity gaps in Kenya, Tanzania, and Mozambique, we assessed tetanus seroprotection by age group and sex. Serologic data were collected in the context of community surveys conducted in rural areas to examine the broad health impact of treatment programs for neglected tropical diseases (NTDs), for example, schistosomiasis, trachoma, soil-transmitted helminths (STH), and lymphatic filariasis (LF). The evaluation included integrated disease serosurveillance with a multiplex bead assay (MBA) for ≥ 30 bacterial, viral, and parasitic antigens, including tetanus. Laboratory. For DBS, blood was collected onto a filter paper with six extensions, each calibrated to absorb 10 μL volume (TropBio Pty Ltd, Queensland, Australia), and then allowed to air-dry ≥ 4 hours. Depending on the country, serum was prepared from whole blood by centrifugation, or serum was eluted from DBS as previously described. 13, 14 TT (Massachusetts Biologic Laboratories, Boston, MA) was coupled to SeroMap microspheres (Luminex Corp., Austin, TX) at the Centers for Disease Control and Prevention (CDC) with 12.5 μg of toxoid per 12.5 × 10 6 beads in buffer containing 50 mM 2-(N-morpholino) ethanesulfonic acid and 0.85% NaCl at pH 5.0, as previously described. 13, 15 Serum samples were diluted 1:400 and assayed in duplicate for IgG (along with control sera) against multiple bacterial, viral, and parasitic disease antigens at CDC in Atlanta, GA, or the Kenya Medical Research Institute (KEMRI) in Nairobi, Kenya, using the conditions previously described. 13 Beads suspended in 100 μL of phosphate-buffered saline in microtiter plates were read in a Bio-Plex 200 instrument equipped with Bio-Plex Manager 6.1 software (Bio-Rad, Hercules, CA), and the average of the median fluorescent intensity values of duplicate wells minus the background fluorescence (MFI-bg) was recorded. Laboratory testing was standardized by running a dilution series of the TE-3 WHO reference serum (National Institute for Biological Standards and Control, United Kingdom). The tetanus MBA was previously validated against the gold-standard double antigen enzymelinked immunosorbent assay with 99% sensitivity and 92% specificity. 13 Ethical considerations. For all sites, adults ≥ 18 years of age provided written consent, children 6-17 years of age provided verbal assent, and adults provided written consent for children < 18 years of age. This evaluation was approved by the Scientific Steering and Ethics Review Committees of KEMRI in Kenya, the National Health Research Ethics Review Committee of the National Medical Research Institute in Tanzania, and the National Bioethics for Health Committee and Instituto Nacional de Saúde in Mozambique. The Human Research Protection Office of the U.S. CDC approved the evaluations in Kenya and Tanzania through reliance on the respective institutional review boards and determined the evaluation in Mozambique to be a nonresearch, public health program evaluation activity according to its human subjects' procedures.
MATERIALS AND METHODS

Survey
Statistical analysis. MBA results in MFI-bg values were transformed to international units per ml (IU/mL) using least squares regression of a log-log plot of a standard curve generated with the TE-3 reference serum. We calculated the percentage of survey participants seroprotected (≥ 0.01 IU/mL) and by antibody-level category (< 0.01, 0.01-0.099, ≥ 0.1-0.9 ≥ 1.0 IU/mL). 13 Absolute differences in seroprotection were calculated by sex and across age groups with 95% Wald asymptotic confidence limits; median antibody concentrations were also calculated for subpopulations. 
RESULTS
Tetanus seroprotection among children 1-4 years, 5-14 years, and persons ≥ 15 years of age was 90%, 66%, and 91% in Mbita District, Kenya, respectively; 89%, 66%, and 73% in Kongwa District, Tanzania; and 88%, 91%, and 79% in Morrupula District, Mozambique. Seroprotection was significantly lower among children 5-14 years versus 1-4 years of age by 24% (95% confidence interval [CI]: 13-35%) in Kenya, and 23% (95% CI: 16-29%) in Tanzania; there was no significant difference (95% CI: −8 to 3%) in Mozambique ( Table 2) .
Among persons ≥ 15 years of age, seroprotection among females and males was 96% and 45% in Kenya, 94% and 28% in Tanzania, and 90% and 64% in Mozambique. Seroprotection was lower among males ≥ 15 years of age than females by 51% (95% CI: 29-73%) in Kenya, 67% (95% CI: 59-75%) in Tanzania, and 26% (95% CI: 20-33%) in Mozambique. In all three countries, there was no significant difference in seroprotection by sex for children 5-14 years and 1-4 years of age (Table 2) .
Median antibody levels among children 1-4 years and 5-14 years of age were 0.139 IU/mL and 0.028 IU/mL in Kenya, 0.113 IU/mL and 0.019 IU/mL in Tanzania, and 0.244 IU/mL and 0.793 IU/mL in Mozambique. Among persons ≥ 15 years of age, median antibody levels for females and males were 0.950 IU/mL and 0.007 IU/mL in Kenya, 0.966 IU/mL and 0.002 IU/mL in Tanzania, and 0.844 IU/mL and 0.047 IU/mL in Mozambique (Table 2) . Antibody levels by age group, 1-4 years, 5-14 years, and ≥ 15 years (males and females), are shown in Table 3 .
DISCUSSION
In summary, we observed evidence of tetanus immunity gaps among men ≥ 15 years of age in community surveys in Kenya, Tanzania, and Mozambique, and among children 5-14 years of age in Kenya and Tanzania. Among these groups, immunity gaps were characterized by low tetanus seroprotection (< 70%) and low antibody concentrations (median ≤ 0.05 IU/mL), which generally correlate with the robustness and duration of protection. 3 Immunity differences in men and women ≥ 15 years of age exist because WRA receive routine TTCV booster doses and men do not, and immunity gaps in older children occur from waning immunity from infant doses. 3 We observed no immunity gap among children 5-14 years of age in Mozambique, who receive two TTCV booster doses through school in first and second grades. 5 Observed sex differences in tetanus seroprotection among persons ≥ 15 years of age in all three ESA countries (range: 26-67%) were similar to the results of historic serosurveys. Adult males had lower tetanus seroprotection than females in a 1990-1991 serosurvey in rural western Kenya (19% versus 69%). 16 In Dar-es-Salaam, Tanzania, 64% seroprotection was observed in a 1999 serosurvey of adult males, whereas 99% seroprotection was observed in a 1997 serosurvey of adult females. 17 [19] [20] [21] In our survey, the smaller difference in tetanus seroprotection (26%) between females and males ≥ 15 years of age in Mozambique is likely explained by provision of two childhood TTCV booster doses. Providing the third WHOrecommended booster in adolescence may be needed to eliminate the sex difference in tetanus immunity among persons ≥ 15 years of age in Mozambique. 3 Differences observed in tetanus seroprotection among children 5-14 years of age compared with 1-4 years of age in Kenya (66% versus 90%) and Tanzania (66% versus 89%) were similar to results from a 1997 serosurvey in Tanzania (54% versus 96%). 22 The low seroprotection we observed among Kenyan children aged 5-14 years of age (66%) was similar to results of 1998 serosurvey in eastern Kenya (63% for 5-14 years of age) and a 1990-1991 serosurvey in western Kenya (58% for 8-11 years of age). 16, 23 These results indicate chronic tetanus immunity gaps in older children from stagnating DTP3 coverage and waning immunity of infant doses. 3, 12 Seroprotection of children 1-4 years of age was similar across the three countries (range: 88-90%). National DTP3 coverage estimated by WHO-UNICEF for annual birth cohorts corresponding to this age group were slightly lower IU/mL = international units per milliliter; LCL = lower confidence limit; UCL = upper confidence limit. *Seroprotection was defined as ≥ 0.01 IU/mL tetanus toxoid IgG.
in Mozambique (range: 74-76%) than in Kenya (range: 85-88%) and Tanzania (range: 86-91%). 12 Variation in vaccination coverage at the district level might explain the relatively high seroprotection we observed among children 1-4 years of age in Mozambique despite lower national coverage.
These serologic data were collected as part of integrated disease serosurveillance and were useful in documenting tetanus immunity gaps in children 5-14 years and men ≥ 15 years of age in ESA countries during the VMMC-associated tetanus outbreak. Our results were considered during the WHO Technical Consultation on Tetanus and VMMC when formulating recommendations for tetanus risk mitigation.
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Tetanus and other NTD control programs have the potential to benefit from multiplex testing in integrated serologic surveillance because of limited resources, attention, and disease-specific data. 13, 24, 25 Including tetanus IgG testing by MBA in national serosurveys can help with monitoring progress towards and maintenance of MNTE. 13 WHO recommends integrating vaccinations given during health service contacts where possible, and opportunities to provide the WHO-recommended TTCV booster doses increasingly exist as countries introduce a second dose of measles-containing vaccine (MCV2) during the second year of life (2YL) and work to develop robust school-based programs for new vaccines that target preadolescents, such as human papillomavirus virus vaccine. 3, 26, 27 Kenya, Tanzania, and Mozambique have established national 2YL delivery platforms with the introduction of MCV2 within the past 3 years. MCV2 coverage by the end of the 2YL in Tanzania improved from 29% in 2014 to 57% in 2015, whereas MCV2 coverage in Kenya was 28% in 2015; data were unavailable for Mozambique where MCV2 was introduced in 2015. 4, 12 All three countries have high net primary school enrollment (> 80%) and gender parity of enrollment (> 90%), making school-based platforms attractive for delivering vaccines at school entry. 27, 28 Existing school-based immunization programs in Mozambique and other ESA countries demonstrate the general feasibility of this approach, but country-specific factors enabling success can vary. 27, 29 Country programs may benefit from technical guidance on how best to introduce TTCV booster doses into the national immunization schedule. Though TTCV is relatively inexpensive (∼$0.10 per dose for TT/Td, ∼$0.20 for DTP, and ∼$1.00 per dose for pentavalent), funding support for operational costs related to the introduction of new vaccination opportunities beyond the first year of life may be helpful in some lower income countries (e.g., grants through GAVI, the Vaccine Alliance). 30, 31 There are limitations of this study. First, the surveys represent convenience samples taken from one district in each country, and are not nationally representative. Second, the limited volume eluted from some DBS collected in Tanzania and Mozambique prevented MBA testing among all participants, especially children 1-4 years of age. Third, other data regarding tetanus immunity from the ESA subregion were limited; there were no nationally representative tetanus serosurveys, and only a small number of surveys with convenience samples were available for comparison. Historic administrative DTP3 coverage from the districts included in our surveys were not available, and we did not collect vaccination data from survey participants, preventing correlation. General limitations of using serology to monitor vaccination programs include failure to seroconvert after vaccination and waning immunity after seroconversion.
In conclusion, tetanus immunity gaps among children 5-14 years and men ≥ 15 years of age have occurred where the WHO-recommended TTCV booster doses are not provided for both sexes in childhood and adolescence. 3 Although our survey results are not generalizable to entire countries or the ESA region, similar immunity gaps may exist in any country without TTCV booster doses. Recent serosurvey results from Bamako, Mali, demonstrated waning tetanus immunity in older children and a sex disparity in adult immunity before the mass campaign with a serogroup A meningococcal TT-conjugate vaccine (MenAfriVac), and serosurvey results after the campaign highlighted the potential to increase tetanus population immunity through use of TT-conjugate vaccines. 32 Moving toward a life course of vaccination approach for tetanus would help countries in sustaining MNTE initially achieved through intensive TT campaigns targeting WRA. Inclusion of TTCV booster doses in national RI schedules, for example, during the 2YL and as part of school-based immunization programs where appropriate, would also help reduce tetanus disease burden in older children and adult males. 
